The Spectra Optia(R) Apheresis System from Terumo Blood and Cell Technologies in combination with UVA PIT system can now be used to provide extracorporeal photopheresis immunotherapy The company is ...

LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...

Terumo's Spectra Optia® Apheresis System Terumo's Spectra Optia® Apheresis System LAKEWOOD, Colo., U.S., and SANTA ROSA, Calif., U.S., July 27, 2022 (GLOBE NEWSWIRE) -- Acute kidney injury (AKI) and ...

LAKEWOOD, Colorado, April 6, 2017 /PRNewswire/ --Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that the SpectraOptia ® Apheresis ...

This resource has been developed to provide practical information and advice relating to NICE medical technologies guidance on Spectra Optia for automatic red blood cell exchange in people with sickle ...

Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia(R) Apheresis System at major conferences Lakewood, Colorado, US, May 25, 2023 – Terumo Blood and ...

The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity. The Food and Drug Administration (FDA) has issued an Emergency Use ...

Following the U.S. FDA’s March 11 approval of Novo Nordisk A/S’ glucagon-like peptide 1 receptor agonist, Wegovy (semaglutide), to reduce the risk of major ...

LAKEWOOD, Colorado, April 6, 2017 /PRNewswire/ -- Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that the Spectra Optia ® Apheresis ...

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...